Xanthus’s Symadex reverses disease in preclinical multiple sclerosis models

Using the experimental autoimmune encephalomyelitis (EAE) model, the effect of Symadex was evaluated during both the acute and chronic phases of EAE in the mouse models. A partial, concentration-dependant decrease in clinical signs was observed in the acute prevention experiment, and chronic treatment resulted in a dose-dependent reduction of clinical scores. Plasma titers in a combined treatment group versus disease controls showed significant changes with a trend towards restoring baseline levels of biomarkers found in naïve controls.

Stephen Karlik, professor of diagnostic radiology at the University of Western Ontario, said: “The evidence that Symadex targets innate immune cell function in the treatment of multiple sclerosis is encouraging and is a foundation for the company’s continued work on Symadex in autoimmune models.”